An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO inhibitor) vs placebo in the treatment of moderate to severe COPD. - CRESCENDO

Exclusion Criteria

• - As judged by the investigator, any evidence of any active medical or psychiatric condition
• or other reason (at SV1 [screening] and SV3 [pre-dose]) which in the investigator's
• opinion makes it undesirable for the participant to participate in the study.
• - Current diagnosis of asthma or past diagnosis of asthma which persisted beyond the age
• of 25 years.
• - Clinically important pulmonary disease other than COPD.
• - Any other clinically relevant abnormal findings on physical examination, laboratory
• testing including haematology, coagulation, serum chemistry, or urinalysis; or chest
• CT scan at screening or randomisation, which in the opinion of the investigator or
• medical monitor may compromise the safety of the participant in the study or interfere
• with evaluation of the study intervention or reduce the participant’s ability to participate
• in the study.
• - History of a clinically significant infection (viral, bacterial, or fungal; defined as requiring
• systemic antibiotics, antiviral, or antifungal medication for > 7 days) within 4 weeks prior
• to SV3 (Day 1) (including unexplained diarrhoea) or clinical suspicion of infection at
• time of dosing.